Cargando…
Global Longitudinal Strain Monitoring to Guide Cardioprotective Medications During Anthracycline Treatment
PURPOSE OF THE REVIEW: Anthracycline chemotherapy carries a risk of myocardial dysfunction and heart failure even at relatively low doses, and the clinical prediction of cancer treatment-related cardiac dysfunction (CTRCD) is inexact. Careful imaging or biomarker surveillance during chemotherapy can...
Autor principal: | Marwick, Thomas H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054886/ https://www.ncbi.nlm.nih.gov/pubmed/35239105 http://dx.doi.org/10.1007/s11912-022-01242-y |
Ejemplares similares
-
Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology
por: Muhandiramge, Jaidyn, et al.
Publicado: (2022) -
Mitochondrial Dynamin-Related Protein Drp1: a New Player in Cardio-oncology
por: Deng, Yali, et al.
Publicado: (2022) -
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023) -
Metabolic Aspects of Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021) -
Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer
por: Kok, Cindy Y., et al.
Publicado: (2021)